Allergic rhinitis is a common and stubborn disease that can even last a lifetime. There are many ways to treat allergic rhinitis, such as nasal hormones, antihistamines, vasoconstrictors, mast cell membrane stabilizers, etc., but they only control the symptoms, which is commonly called “treating the symptoms” and requires long-term use and has certain side effects. Specific immunotherapy (SIT) is a recommended method of desensitization therapy. The principle is to process and purify the active ingredients of specific allergens (such as mites) and use them as allergens in desensitization preparations. The patient is exposed to the allergen at a low dose and the dose is gradually increased to a maintenance dose and then continued for a sufficient duration to stimulate the immune system to develop immune tolerance, i.e. “paralysis”. When the patient is exposed to the allergen again, the allergic symptoms are significantly reduced or no longer occur. Therefore, desensitization treatment can be called the “cure”. In 1998, the WHO (World Health Organization) recommended desensitization as “the only treatment that can affect the underlying mechanisms of allergic diseases and thus alter their natural course”. Sublingual desensitization therapy (SLIT) not only greatly reduces the incidence and severity of adverse reactions; it is also easy to use and can be received at home. This has expanded the population of children under 5 years of age who can also receive desensitization therapy. At present, there are localized allergen desensitization preparations in China, such as mite desensitization preparations that can match the allergens that cause allergic reactions in Chinese patients, and can be used to treat allergic rhinitis and asthma in China in a more targeted manner.